Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections

The rise in resistant Gram-negative pathogens continues to challenge clinicians treating infections. These resistant infections have inspired the development of new antimicrobial agents, including ceftolozane–tazobactam, a novel β-lactam/β-lactamase inhibitor combination approved by the US Food and...

Descripción completa

Detalles Bibliográficos
Autores principales: Giancola, Stephanie E, Mahoney, Monica V, Bias, Tiffany E, Hirsch, Elizabeth B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878668/
https://www.ncbi.nlm.nih.gov/pubmed/27279744
http://dx.doi.org/10.2147/TCRM.S83844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878668/
https://www.ncbi.nlm.nih.gov/pubmed/27279744
http://dx.doi.org/10.2147/TCRM.S83844

Ejemplares similares